{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"196","spread":"196","upperLimit":"274","value":"241"},{"groupId":"OG001","lowerLimit":"278","spread":"278","upperLimit":"372","value":"326"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from date of randomization (Day 1) to death due to any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) of the first subject to end of follow upto 1710 days","title":"Overall Survival (OS)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"days"}